Xenon Pharmaceuticals Inc., of Burnaby, British Columbia, said it started a phase I trial of epilepsy candidate XEN-1101, an orally administered Kv7 potassium channel opener that has the potential to treat both adult as well as rare pediatric genetic forms of epilepsy.